1. X
  2. Harpreet Singh, MD
Log inSign up
Harpreet Singh, MD
1,081 posts
Image
user avatar
Harpreet Singh, MD
@harpreet_md
Chief Medical Officer, Precision for Medicine 🧬🥼⚕️ Former FDA Oncology Director
Washington, DC
precisionformedicine.com
Joined June 2017
817
Following
1,927
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Jun 6, 2020
    When I leave work, I’m a wife, daughter, and stepmom to 3 Black men. When any of them leave the house, we say “love you, stay safe” - it’s part of our lives. I hope that we can all continue this work, checking our biases. For my family, and for my daughter Norah. #BLM
    Image
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Nov 5, 2021
    🪔 Happy Diwali from ours to yours 🪔
    Image
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Mar 3, 2022
    FDA pushes cancer trials to include more elderly people | Science | AAAS
    science.org
    FDA pushes cancer trials to include more elderly people
    New guidance aims to improve understanding of drug safety, effectiveness in older adults
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    May 31, 2019
    Patient advocacy at its finest. Beverly Canin asking how we can empower more oncologists to offer clinical trials to ALL patients. Leaning from every patient...#ASCO19 @ASCO
    Image
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Nov 12, 2023
    Happy Diwali 🪔 Wishing you light, love, peace and prosperity this season ✨
    Image
    9.4K09.4K
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    May 22, 2024
    I am thrilled to join Precision for Medicine as Chief Medical Officer! Looking forward to leveraging my deep medical knowledge and regulatory expertise to drive novel treatments forward for patients with cancer and rare diseases. ⚕️🥼🧬
    user avatar
    Precision for Medicine
    @Precision4Med
    May 22, 2024
    Harpreet Singh, MD has joined Precision as Chief Medical Officer after over a decade of experience at FDA & National Cancer Institute. Dr. Singh oversaw multiple oncology & rare disease programs at the FDA. Her insights will be invaluable to our clients. hubs.ly/Q02y36MN0
    Image
    GIF
    25K025K
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Sep 9, 2020
    This is the 8th approval for NSCLC in the year 2020!
    user avatar
    FDA Oncology
    @FDAOncology
    Sep 9, 2020
    On September 4, 2020, FDA granted accelerated approval to pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. ow.ly/Zaf550BlXmQ
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    May 8, 2020
    Today, FDA approved selpercatinib for patients with: ✅ RET-fusion NSCLC ✅ RET-mutant MTC ✅ RET-fusion thyroid cancer ✳️ all indications line-agnostic 3️⃣ months ahead of FDA goal date .@FDAOncology #lcsm #thycsm
    user avatar
    FDA Oncology
    @FDAOncology
    May 8, 2020
    FDA approved Retevmo (selpercatinib) to treat non-small cell lung cancer and thyroid cancers in patients whose tumors have a RET gene mutation or fusion. Retevmo is the 1st therapy approved specifically for cancer with RET gene alterations. #lcsm #thycsm go.usa.gov/xv7Fw
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Jun 4, 2024
    🥼First ASCO as Chief Medical Officer of Precision for Medicine 🧬Loved hearing about so much great science and diving right in help biotech bring more promising therapies to patients! #ASCO24 #CMO #biotech @Precision4Med
    Image
    7.3K07.3K
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Sep 11, 2021
    Thrilled to see this in print. Thank you @theNASEM @bertagnollimm @FDAOncology for your commitment to our Older Adults with Cancer — Addressing Gaps in Evidence | NEJM
    Image
    nejm.org
    Treatment of Older Adults with Cancer — Addressing Gaps in Evidence | NEJM
    Older adults with cancer are underrepresented in clinical research. Because of insufficient data, such patients and their physicians must make life-altering treatment decisions without adequate evi...
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Aug 3, 2020
    ✨Happy 2nd birthday to our sweet Norah Grace. ✨
    Image
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    May 28, 2021
    Wonderful news today for patients and kuddos to the Thoracic team at @FDAOncology for expediting this critical approval.
    user avatar
    U.S. FDA
    @US_FDA
    May 28, 2021
    Today, FDA approved the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. go.usa.gov/x6CVW
    Image
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    May 31, 2019
    Thrilled to join my friends and colleagues @ASCO but leaving these smiles behind doesn’t get easier 💗 see you soon Chicago ✈️ #ASCO19
    Image
  • user avatar
    Harpreet Singh, MD
    @harpreet_md
    Jun 21, 2020
    Thanks ⁦@nytimes⁩ for interviewing me for this piece. Eligibility criteria for COVID-19 trials should be closely examined, with concerted efforts to enroll older adults. #COVID19
    Image
    Older Adults May Be Left Out of Some Covid-19 Trials (Published 2020)
    From nytimes.com
Advertisement
Advertisement